News
Market and company headlines
BMYAll
Loading
03:00-09:00Yesterday2 Stories
Bristol-Myers Squibb (NYSE:BMY): Weighing Dividend Quality for Income Investors
See how the Best Dividend Stocks screen balances high yield with profitability and health, using Bristol-Myers Squibb as a dividend case study.
Piper Sandler Maintains Overweight on Bristol-Myers Squibb, Lowers Price Target to $78
Piper Sandler analyst David Amsellem maintains Bristol-Myers Squibb (NYSE:BMY) with a Overweight and lowers the price target from $82 to $78.
21:00Oct 241 Story
16:00-22:00Oct 232 Stories
Bristol Myers Squibb (BMY) Bets On AI Drug Discovery And Wider Trial Access
Bristol Myers Squibb (NYSE:BMY) has entered multi year AI drug development partnerships with Pathos AI and Tempus AI. The agreement gives Bristol Myers Squibb exclusive access to Pathos AI's discovery platform for neuroscience projects. Tempus AI will provide multi year data licensing that connects real world patient information with AI tools across Bristol Myers Squibb's pipeline. The company also launched a national collaboration with the Institute for Healthcare Improvement to broaden...
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Bristol Myers Squibb (BMY) reached $61.48 at the closing of the latest trading day, reflecting a -2.41% change compared to its last close.
08:00-16:00Oct 232 Stories
BMY Stock Falls 2% After Patient Death In Early Multiple Sclerosis CAR T Trial
The death of the patient with highly active relapsing MS occurred after the study’s data cutoff.
Bristol-Myers Spokesperson Says Grade 5 Event That Was Disclosed As Part Of Data Disclosure At MS Toronto Occurred After Trial Pause; Working Closely With FDA To Restart Trial As Soon As Possible, With The Goal Of Resuming Enrollment In Early 2027; Grade 5 Event That Was Disclosed Was Not Related To Our Decision To Pause The BreakFree Program
- Reuters
05:00Oct 231 Story
08:00-10:00Oct 222 Stories
Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Bristol-Myers Squibb (BMY) Is Back In The Spotlight
Bristol-Myers Squibb (BMY) is back in focus after a fresh wave of clinical updates, including new oncology data headed to the ESMO 2026 Congress and recent Phase 3 readouts in cancer and pulmonary fibrosis. All this clinical news is landing after a strong run in Bristol-Myers Squibb’s shares this year. The year-to-date share price return of 14.33% and the 1-year total shareholder return of 43.82% indicate momentum that has cooled slightly in recent weeks as traders reassess risk and pipeline...
03:00-10:00Oct 212 Stories
Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?
Bristol Myers faces mounting generic competition across its legacy portfolio, while Eliquis delivers strong growth and Revlimid shows resilience amid pricing and market pressures.
Bristol-Myers Squibb: Why I'm Bullish Ahead Of Q3 Earnings
Bristol-Myers Squibb yields about 4.3% and trades at 9.1x forward EV/EBIT. Read why BMY stock offers an attractive risk/reward profile.
12:00Oct 201 Story
09:00-18:00Oct 192 Stories
Bristol Myers Squibb (BMY) Heads To ESMO 2026 With New Oncology Data
Bristol-Myers Squibb (NYSE:BMY) plans to present late-breaking oncology data at ESMO 2026, including new results for pumitamig. The company will also share milestone findings for izalontamab brengitecan (iza bren) that focus on next-generation cancer modalities. Updated long-term survival data for the Opdivo plus Yervoy immunotherapy combination are scheduled for disclosure at the same meeting. The ESMO 2026 data on pumitamig, iza bren and Opdivo plus Yervoy sits against a wider backdrop our...
Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?
Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) are almost opposites in the pharmaceutical market. One is trying to replace revenue from aging blockbusters, while the other is struggling to keep pace with demand for its newest ones. Yahoo Finance’s most recently available valuation statistics show that Bristol Myers trades at 9.36 times […]
12:00-14:00Oct 152 Stories
Bristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
Bristol-Myers Squibb's (BMY) LPA1 antagonist admilparant can still be viable despite recent mixed re
How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb (BMY) Investors
Earlier this week, Bristol Myers Squibb reported positive Phase 3 results for three key programs: RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, admilparant in idiopathic pulmonary fibrosis where only the lower dose met the primary endpoint, and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. Together, these late-stage readouts highlight both the promise and complexity of Bristol Myers Squibb’s next generation portfolio, with new oncology,...
08:00Oct 141 Story
12:00-16:00Oct 132 Stories
What Does Bristol-Myers Squibb Offer That Pfizer Does Not?
Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market exclusivity. Both drugmakers point to 2028 as the year that matters. Pfizer is acquiring drugs and cutting costs to bridge the gap, while Bristol Myers still relies on Eliquis, an older drug that continues to grow. So what did each company tell investors at its latest report about how that replacement is going.
BMY Reports Mixed Phase III Trial Results, Stock Down
Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.
10:00-12:00Oct 132 Stories
Bristol Myers Squibb (BMY) Stock Trades At A Discount Following Its 38% Run
Bristol-Myers Squibb has delivered a strong 38.1% share price gain over the past year, even as shorter term moves have been weaker. This naturally raises the question of whether that climb is fully supported by the earnings the business is generating today. That 38.1% one year return puts more weight on the question of whether the current valuation is still in line with what Bristol-Myers Squibb actually earns. Fresh positive late stage trial results across cancer, cardiology and respiratory...
What Could Bristol Myers Squibb (BMY) Two Phase 3 Wins Change?
Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 data for admilparant in idiopathic pulmonary fibrosis and RYZ101 in gastroenteropancreatic neuroendocrine tumors. Admilparant showed significant clinical benefits and a favorable safety profile in idiopathic pulmonary fibrosis, targeting a serious chronic lung disease. RYZ101 improved progression free survival in patients with gastroenteropancreatic neuroendocrine tumors, supporting upcoming regulatory discussions. The Phase 3 wins...
09:00-11:00Oct 52 Stories
BMY or ARGX: Which Is the Better Value Stock Right Now?
BMY vs. ARGX: Which Stock Is the Better Value Option?
Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt
Investing.com -- Shares of Bristol-Myers Squibb Co. (NYSE: BMY) fell 2.5% in premarket trading after Leerink Partners downgraded the pharmaceutical giant from Outperform to Market Perform, citing growing skepticism surrounding key candidates in the company’s drug development pipeline.
05:00-09:00Oct 52 Stories
Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59
Leerink Partners analyst David Risinger downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and lowers the price target from $73 to $59.
05:00Oct 31 Story
04:00-09:00Sep 302 Stories
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J
The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026
15:00-22:00Sep 292 Stories
How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors
In September 2026, Bristol Myers Squibb reported first-time, pivotal Phase 3 EXCALIBER-RRMM data showing ZENBEXUS (iberdomide) plus daratumumab and dexamethasone produced a statistically significant, clinically meaningful improvement in minimal residual disease–negative complete responses versus a standard daratumumab-based regimen in relapsed or refractory multiple myeloma. This MRD-focused outcome is particularly important because it informs the accelerated approval pathway for ZENBEXUS...
Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial
Bristol-Myers Squibb (NYSE:BMY) reported pivotal Phase 3 EXCALIBER-RRMM data for ZENBEXUS in relapsed or refractory multiple myeloma. The Phase 3 trial showed a clinically meaningful advantage in MRD-negative complete response rates versus standard therapy. The first full readout of EXCALIBER-RRMM highlights potential clinical and commercial relevance for ZENBEXUS in a crowded myeloma treatment field. The MRD-negative complete response results from EXCALIBER-RRMM are important, but investors...
06:00Sep 291 Story
17:00-21:00Sep 282 Stories
Could Bristol-Myers Squibb (BMY)’s New Myeloma Data Reshape its Growth Outlook?
On September 25, Bristol-Myers Squibb Company (NYSE:BMY) announced milestone results from its Phase 3 EXCALIBER-RRMM trial evaluating Zenbexus in combination with daratumumab and dexamethasone (ZDd) for relapsed or refractory multiple myeloma. At a median follow-up of 15.7 months across 420 patients, ZDd demonstrated a statistically significant improvement in minimal residual disease (MRD)-negative complete response rates […]
Bristol-Myers Squibb (BMY) is Building its Next Growth Engine. Can It Replace Lost Revenue?
On September 8, Bristol-Myers Squibb Company (NYSE:BMY) announced positive Phase 2 results from its registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel (arlo-cel) in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM). The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful overall response rate (ORR) alongside strong complete response rates […]
06:00Sep 281 Story
12:00Sep 241 Story
08:00-11:00Sep 222 Stories
Eli Lilly Breaks Ground on $6.5B Generation Park Facility
A $6.5B Eli Lilly biomanufacturing facility broke ground at Houston’s Generation Park, Texas’ largest pharmaceutical investment to date.
AISB Network Launches AISB Bind to Improve Prediction of How Molecules Bind for Virtual Screening and Lead Optimization
BERLIN, September 22, 2026--AISB Network launches AISB Bind to improve prediction of how molecules bind for virtual screening and lead optimization
07:00Sep 221 Story
10:00-18:00Sep 212 Stories
Onco360® is a participating specialty pharmacy in the ZENBEXUS™ (iberdomide) limited dispense network
LOUISVILLE, Ky., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a participating pharmacy by Bristol-Myers Squibb for ZENBEXUS™ (iberdomide), indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.¹ “Onco360 is grateful for the
What Would It Take For Pfizer To Cut Its Dividend?
Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change.
08:00Sep 201 Story
09:00-12:00Sep 184 Stories
BMY vs. ARGX: Which Stock Is the Better Value Option?
BMY vs. ARGX: Which Stock Is the Better Value Option?
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
Should Value Investors Buy Bristol Myers Squibb (BMY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
00:00-09:00Sep 182 Stories
Bristol Myers Squibb (BMY) Funds India Lung Cancer Screening Research Beyond Smoking
Bristol-Myers Squibb (NYSE:BMY) is funding lung cancer screening research in India that targets risks beyond smoking. The Bristol Myers Squibb Foundation is backing two clinical trials at the All India Institute of Medical Sciences in New Delhi. The projects aim to build localized lung cancer risk models and screening tools that include nonsmokers and people exposed to high air pollution. The Bristol Myers Squibb Foundation move into India focused lung cancer screening sits alongside wider...
Bristol-Myers Squibb (BMY), What Is Behind The Fresh Attention?
Bristol-Myers Squibb (BMY) just paired new clinical data with income news, reporting positive two year Sotyktu results in psoriatic arthritis and affirming a quarterly dividend of US$0.63 per share for November payment. That mix of solid clinical data and a confirmed dividend comes as Bristol-Myers Squibb’s share price has climbed 16.37% over the past 90 days and 17.55% year to date, while the 1-year total shareholder return of 44.42% points to momentum that has been building rather than...
17:00Sep 171 Story
04:00Sep 101 Story
11:00-18:00Sep 92 Stories
Could Bristol-Myers Squibb (BMY) Outperform Novartis (NVS) as CAR-T Safety Concerns Shake the Sector?
The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently […]
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.
07:00-09:00Sep 93 Stories
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort
NORTHAMPTON, MA / ACCESS Newswire / September 9, 2026 / Organizations Across Sectors Unite Through the Winn Awards to Advance Better Science For AllPreviously published by the Robert A. Winn Excellence in Clinical Trials Award ProgramA growing coalition of pharmaceutical companies, nonprofit organizations, academic institutions, and clinical research leaders came together through the Robert A.
Latus Bio Appoints Donald Hayden as Chairman of the Board and Michael MacLean as Independent Director and Audit Committee Chair
PHILADELPHIA & BOSTON, September 09, 2026--Latus Bio, Inc. (Latus), a biotechnology company engineering gene therapies at scale, today announced the appointments of Donald Hayden, M.B.A., as Chairman and Michael MacLean as independent director and Chair of the Audit Committee of the Latus Board of Directors. Mr. Hayden and Mr. MacLean bring decades of executive leadership experience in driving successful biopharmaceutical companies through key value inflection points and delivering advanced medi
04:00-06:00Sep 92 Stories
SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026
Potential extends to earlier-line use, injection-averse patients and new immune-mediated indicationsDublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The "SOTYKTU Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive assessment of SOTYKTU (deucravacitinib) across approved and potential immune-mediated inflammatory disease indications. The analysis covers the seven major markets (7MM): the United States, Germany, France,
Giovanni Caforio Appointed Operating Advisor to CD&R Funds
CD&R (or the "Firm") today announced the appointment of Giovanni Caforio as an Operating Advisor to CD&R funds. The Firm believes his 35-year career in the international biopharmaceutical industry will be invaluable as he supports CD&R funds in identifying and evaluating new investment opportunities within healthcare, as well as working with its portfolio companies globally.
10:00-12:00Sep 82 Stories
Here’s How Much You Need Invested to Collect $1,000 a Month in Dividends
Collecting $1,000 a month in dividends sounds simple until you realize the capital required shifts every time prices move, and choosing the wrong yield can leave you exposed to a dividend cut when you can least afford it.
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.